JP2022511788A - Ｓ１ｐ１受容体に関連する状態を治療する方法 - Google Patents

Ｓ１ｐ１受容体に関連する状態を治療する方法 Download PDF

Info

Publication number
JP2022511788A
JP2022511788A JP2021530816A JP2021530816A JP2022511788A JP 2022511788 A JP2022511788 A JP 2022511788A JP 2021530816 A JP2021530816 A JP 2021530816A JP 2021530816 A JP2021530816 A JP 2021530816A JP 2022511788 A JP2022511788 A JP 2022511788A
Authority
JP
Japan
Prior art keywords
compound
individual
solvate
pharmaceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021530816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511788A5 (https=
JPWO2020112880A5 (https=
Inventor
スネハル ナイク
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022511788A publication Critical patent/JP2022511788A/ja
Publication of JP2022511788A5 publication Critical patent/JP2022511788A5/ja
Publication of JPWO2020112880A5 publication Critical patent/JPWO2020112880A5/ja
Priority to JP2024195531A priority Critical patent/JP2025024035A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
JP2021530816A 2018-11-30 2019-11-26 Ｓ１ｐ１受容体に関連する状態を治療する方法 Withdrawn JP2022511788A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195531A JP2025024035A (ja) 2018-11-30 2024-11-08 Ｓ１ｐ１受容体に関連する状態を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773936P 2018-11-30 2018-11-30
US62/773,936 2018-11-30
US201962850464P 2019-05-20 2019-05-20
US62/850,464 2019-05-20
PCT/US2019/063413 WO2020112880A1 (en) 2018-11-30 2019-11-26 Methods of treating conditions related to the s1p1 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195531A Division JP2025024035A (ja) 2018-11-30 2024-11-08 Ｓ１ｐ１受容体に関連する状態を治療する方法

Publications (3)

Publication Number Publication Date
JP2022511788A true JP2022511788A (ja) 2022-02-01
JP2022511788A5 JP2022511788A5 (https=) 2022-12-05
JPWO2020112880A5 JPWO2020112880A5 (https=) 2022-12-05

Family

ID=68966033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530816A Withdrawn JP2022511788A (ja) 2018-11-30 2019-11-26 Ｓ１ｐ１受容体に関連する状態を治療する方法
JP2024195531A Pending JP2025024035A (ja) 2018-11-30 2024-11-08 Ｓ１ｐ１受容体に関連する状態を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195531A Pending JP2025024035A (ja) 2018-11-30 2024-11-08 Ｓ１ｐ１受容体に関連する状態を治療する方法

Country Status (9)

Country Link
US (1) US20220023258A1 (https=)
EP (1) EP3886841A1 (https=)
JP (2) JP2022511788A (https=)
KR (1) KR102824401B1 (https=)
CN (2) CN118649163A (https=)
AU (1) AU2019387212A1 (https=)
CA (1) CA3120706A1 (https=)
IL (1) IL283414A (https=)
WO (1) WO2020112880A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) * 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2013518106A (ja) * 2010-01-27 2013-05-20 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
JP2018504398A (ja) * 2015-01-06 2018-02-15 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) * 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3355896A2 (en) * 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
MA47504A (fr) * 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) * 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2013518106A (ja) * 2010-01-27 2013-05-20 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
JP2018504398A (ja) * 2015-01-06 2018-02-15 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patient", ARENA PHARMACEUTICALS, JPN6023045364, 19 March 2018 (2018-03-19), ISSN: 0005379995 *
THE AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 113, JPN6023045363, October 2018 (2018-10-01), pages 327 - 328, ISSN: 0005379994 *
TURK J GASTROENTEROL, vol. 27, JPN6023045366, 2016, pages 149 - 155, ISSN: 0005379996 *
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, vol. Vol.6(8S), JPN6023045362, October 2018 (2018-10-01), pages 94 - 95, ISSN: 0005379993 *
日消誌, vol. 115, no. 3, JPN6023045368, March 2018 (2018-03-01), pages 262 - 271, ISSN: 0005379997 *

Also Published As

Publication number Publication date
KR20210098487A (ko) 2021-08-10
US20220023258A1 (en) 2022-01-27
JP2025024035A (ja) 2025-02-19
KR102824401B1 (ko) 2025-06-25
AU2019387212A1 (en) 2021-06-24
CN113226307A (zh) 2021-08-06
EP3886841A1 (en) 2021-10-06
WO2020112880A1 (en) 2020-06-04
CA3120706A1 (en) 2020-06-04
IL283414A (en) 2021-07-29
CN118649163A (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
JP2022511788A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
JP7219732B2 (ja) Ｓ１ｐ１受容体に関連する状態の処置方法
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
ES2987794T3 (es) Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
WO2021163355A1 (en) Formulations and methods of treating conditions related to the s1p1 receptor
HK40116488A (zh) 治疗与s1p1受体有关的病况的方法
CN115038438A (zh) 治疗与s1p1受体相关的病症的方法
KR102958419B1 (ko) S1p₁ 수용체와 관련된 병태의 치료 방법
HK40116740A (zh) 治疗与s1p1受体有关的病况的方法
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
HK40050237B (en) Methods of treating conditions related to the s1p1 receptor
HK40050237A (en) Methods of treating conditions related to the s1p1 receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241108